Does Intravenous Immunoglobulin Ivig Interact with Ravulizumab?
Intravenous Immunoglobulin Ivig and Ravulizumab have a moderate drug interaction according to U.S. FDA drug labeling data. Concomitant use can reduce serum ravulizumab concentrations and requires a supplemental dose of ULTOMIRIS. The mechanism involves reduces serum ravulizumab concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Ravulizumab Class
- Complement Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Intravenous Immunoglobulin Ivig and Ravulizumab occurs because reduces serum ravulizumab concentrations. Clinically, this means concomitant use can reduce serum ravulizumab concentrations and requires a supplemental dose of ultomiris. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Intravenous Immunoglobulin Ivig and your doctor is considering prescribing Ravulizumab (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider